Design Therapeutics is developing DT-216P2, a small-molecule drug candidate for Friedreich's Ataxia (FA) using its proprietary GeneTAC platform targeting repeat-expansion diseases. Their RESTORE-FA trial has produced promising data, enhancing the drug's credibility. The company plans to clarify the drug's regulatory path with the FDA by Q4 2026 and has sufficient funding to continue operations through 2029, supporting optimism about future progress and milestones.
Modern Therapy Group has introduced a virtual intensive outpatient program (IOP) designed for adults dealing with depression, anxiety, trauma, and other mental health issues. This program offers structured, clinician-led treatment five days a week vi...
Meyer Wilson Werning, an investor protection law firm, is investigating UBS advisor Daniel Merithew Allen for allegedly recommending unapproved investments in 99 Acquisition Group LLC to clients. This practice, known as "selling away," violates FINRA...
NEWMEDIA.COM highlights a major shift in digital marketing where AI Visibility Infrastructure integrates search, authority, content, and analytics to ensure brands are discoverable and recommended by AI systems. Traditional search rankings are becomi...
An insider at Oruka Therapeutics sold 105,000 shares valued at $6.2 million. Such a large sale by someone within the company could indicate changes in confidence or strategy. Investors should watch for further developments or official statements from...
The official $HODL coin, created by GameKyuubi—the original author of the famous 2013 "HODL" post—has expanded to Ethereum with a new 1:1 cross-chain bridge powered by LayerZero. This bridge allows holders to transfer $HODL tokens instantly between S...
